Information Provided By:
Fly News Breaks for August 30, 2017
PCRX
Aug 30, 2017 | 07:03 EDT
Canaccord Genuity analyst Dewey Steadman lowered his price target for Pacira Pharmaceuticals to $48 saying the recently reported July IMS data show a modest downtick in year-over-year Exparel sales and volume comps. The data are disappointing following a strong July but Exparel volumes and revenue should accelerate as the year progresses, Steadman tells investors in a research note. The analyst lowered his estimates for Pacira but keeps a Buy rating on the shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX